The University of Washington School of Medicine (Seattle) is enrolling 20 people into their newest clinical trial involving the her2/neu vaccine given in conjunction with herceptin. The trial is ""Phase I-II Study of Combination Immunotherapy for the Generation of HER2/neu (HER2) Specific Cytotoxic T Cells (CTL) in vivo. This vaccine has already been given in Phase I trials and produced some immune response. This trial will combine with herceptin to see if that enhances the immune response" but will be the first time the combination has been tried. At any rate it is very exciting and I know there were many who were interested in the initial trial that were excluded because of herceptin - here's your chance. Contact: Andrea York 206.616.9538 or email:
ay5@u.washington.edu for further information.
Kitty